Guangzhou Sino-Israel Bio-Industry Investment Fund 2 LLP has made a strategic investment of US$ 6m (CHF 5.17m) in Bioversys, a specialist in antibacterial products for infections caused by multi-drug resistant bacteria. This funding aligns with the company’s decision to expand the clinical development of its lead asset BV100 in China. The study is expected to start in 1H 2025 in preparation for a global Phase 3 registrational study.
